You can find further details on the Clinical Fellowship page on the EAN website.

25 November: Mark the dates for the 30th Alzheimer Europe Conference 2020!

Launch Alzheimer's Disease (AD) Detect and Prevent Newsletter

Positive outcome of the open letter adding “research” to the title of the Commissioner Designate Mariya Gabriel

Brain health back on the agenda in the European Parliament. Research policy still pending.

Effective as of November, the EAN Board decided to create a new Neuroscience/translational Scientific Panel.

Dear Prof. McNicholas, thank you for accepting this interview. In light of the work towards an MoU with EAN, we would like to introduce the ESRS to the EANpages readers.

First of all, I would like to wish you a very happy holiday season and every success in the New Year! As we approach the end of 2019, we can look back on another highly productive year for EAN with yet another successful congress. The number of delegates was an all-time high and we can boast on eminent keynote speakers, and well-attended scientific sessions and teaching courses. As our main mission is to promote excellence in neurology across Europe, we aim to continue this success and hard work into the future. With that in mind, I would like to tell you a little about some recent changes and plans that EAN has in order to support this important mission to the benefit of neurologists and patients throughout Europe.

For December 2019, we have selected: Cree et al., Inebilizumab for the treatment of neuromyelitis optica (N-MOmentum): a double-blind, randomised placebo-controlled  phase 2/3 trial Lancet 2019 Epub ahead of print Sept 5.

Armenia is located in the South Caucasus, bordered by Georgia from the north, Iran from the South, Azerbaijan from the north-east and the south-west and Turkey from the west. The Republic of Armenia occupies a territory of 29,800 square kilometres. The capital is Yerevan. According to the general census of 2011 the population of Armenia is 3,018,854, 1.1 million of whom live in Yerevan.

Findings suggest narcolepsy type 1 to be a T-cell mediated autoimmune disease targeting hypocretin-producing neurons.

Nakalanga syndrome: Clinical characteristics, potential causes, and its relationship with recently described Nodding syndrome

President Prof Fazekas continues to recover.

ERN-RND provides educational webinars on rare neurological and neuromuscular diseases - in collaboration with the European Reference Network for Rare Neuromuscular Diseases (EURO-NMD) and the European Academy of Neurology (EAN).

New treatment options for pediatric convulsive status epilepticus after failure of first-line benzodiazepines